Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.
The post Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent? appeared first on Investor's Business Daily.
